
    
      An 8-week, randomized, double-blind, placebo-controlled, parallel-group adjunctive therapy
      trial. The study consists of subjects with insomnia related to Generalized Anxiety Disorder
      who will be treated for 10 weeks with open-label escitalopram oxalate 10 mg/day at bedtime,
      and randomized to receive either eszopiclone 3 mg nightly or placebo nightly for 8 weeks.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  